Abstract: Disclosed are a NFC antenna module which maximizes antenna performance by mounting a radiation sheet in such a manner as to partially overlap with an antenna sheet and a portable terminal comprising the same. The disclosed NFC antenna module comprises: an electromagnetic wave shielding sheet; an antenna sheet laminated on the electromagnetic wave shielding sheet and having a radiation pattern formed along the outer periphery of a central portion thereof; and a radiation sheet laminated on the antenna sheet so as to form an overlapping area with the radiation pattern and having a recess formed therein, through which the central portion is exposed.

Abstract: Disclosed are a wireless communication antenna module and a portable terminal including the same for maximizing the performance of an antenna by mounting a radiation sheet so as to partially overlap with an antenna sheet. The disclosed wireless communication antenna module comprises: the antenna sheet provided with a radiation pattern and is installed on a portable terminal main body or a battery pack; and the radiation sheet installed on a rear-surface housing of the portable terminal, wherein an overlapping area is formed by laminating the antenna sheet and the radiation sheet in an overlapping manner when the portable terminal main body and the radiation sheet are coupled.

Abstract: Disclosed are a wireless communication antenna module and a portable terminal including the same for maximizing the performance of an antenna by mounting a radiation sheet so as to partially overlap with an antenna sheet. The disclosed wireless communication antenna module comprises: the antenna sheet provided with a radiation pattern and is installed on a portable terminal main body or a battery pack; and the radiation sheet installed on a rear-surface housing of the portable terminal, wherein an overlapping area is formed by laminating the antenna sheet and the radiation sheet in an overlapping manner when the portable terminal main body and the radiation sheet are coupled.

Abstract: A system and method provided for recruiting new membership through value sending from existing members. The value can be coupons, discount offers, membership points or payment vouchers in physical and/or electronic formats. The method is an active way to recruit new members through the social network of existing members. Once a member in the system sends value from their account to the non-members by simply entering his/her mobile phone number as identification of the receiver, the receiver will receive the notification through short message service (SMS) or similar service of the value received. The receiver uses his/her mobile number together with the password disclosed within the notification message for redeeming the received value at the point of purchase in the corresponding public facing business. In addition, the receiver can update his membership details through a registration webpage on the internet.

Abstract: A method of determining an optimum recording power with respect to a rewritable optical recording medium with multiple layers. The method includes the operations of writing a recording signal to an unrecorded area of a power calibration area (PCA) of the rewritable optical recording medium using a predetermined recording power, and measuring characteristics of the recording signal, determining whether the measured recording signal characteristics have a saturation area, computing a recording power at a saturation point of the recording signal characteristics when the recording signal characteristics have the saturation area, and determining an optimum recording power by multiplying the recording power at the saturation point by a predetermined value. An optimum recording power is determined by using the saturation point of the recording signal characteristic curve such that optimum recording power can be accurately obtained when the optimum recording power is in the saturation area.

Abstract: A method of erasing a power calibration area (PCA) for determining optimum power, including applying a command for recording data, detecting a non-recorded PCA area for performing optimum power control (OPC), and when all the PCA area is used and no non-recorded PCA area is detected, performing erasing of the PCA area at least twice. Accordingly, since the PCA area is erased at least twice, reliability of the optimum recording power determined by performing the OPC is much improved.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m, n and q are defined as in the specification, and the pharmaceutically acceptable salts thereof. The compounds have calcium entry blocking activity with selectivity for cerebral blood vessels, and have protective activity against some of the deleterious effects resultant upon cerebral ischemia.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives and the pharmaceutically acceptable salts thereof are useful for treating mammals having any of a variety of disease states. These disease states include: 1) diseases treated by direct neuronal protection, including focal and global ischemia, spinal injuries, and head trauma, and neurological diseases including Alzheimer's and Huntington's chorea; 2) uraemic and hyponatraemic encephalopathy; 3) diseases treated by diuresis; 4) diseases treated by calcium channel antagonism, including cardiovascular diseases (i.e. hypertension, angina, stable and unstable angina, Prinzmetal angina, arrhythmia, thrombosis, embolism, and congestive heart failure including chronic or acute cardiac failure), diseases characterized by ischemia of lower legs due to peripheral vascular disease (e.g., intermittent claudication), diseases characterized by spasms of smooth muscle (i.e.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two, provided that when R.sup.3 is hydroxy, n is oneor two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two, provided that when R.sup.3 is hydroxy, n is one or two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two,provided that when R.sup.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two, provided that when R.sup.3 is hydroxy, n is one or two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 lower alkyl, hydroxy, or hydrogen;R.sup.4 aryl or hydrogen;R.sup.5 aryl or hydrogen;m is two or three;n is zero, one or two,provided that when R.sup.3 hydroxy, n is one or two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilipsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.

Abstract: Novel arylsulfonyl-dihydropyridine derivatives which are useful as calcium entry-blocker cardiovascular agents have the formula: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen, lower alkyl, or lower alkoxyalkyl;R.sup.2 is hydrogen or chloro; andR.sup.3 is hydrogen, lower alkyl, or lower alkoxyethyl.A novel process using chiral sulfoxide reagents efficiently produces single isomers of these and other sulfonyl dihydropyridines.

Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two,provided that when R.sup.3 is hydroxy, n is one or two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.